- Lung cancer therapy including novel compounds and early phase trials
- Breast cancer therapeutics including novel compounds and early phase trials
- Health services research
- Economics of lung cancer therapy
- Treatment decision-making in advanced cancer, including development of patient decision aids
- Patient-physician communication
Curr Oncol. 2019 Apr;26(2):89-93
Lung Cancer. 2019 May;131:86-89
J Hematol Oncol. 2019 Apr 25;12(1):45
J Thorac Dis. 2019 Mar;11(Suppl 3):S422-S424
Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer.
Clin Cancer Res. 2019 Apr 15;:
Genetic interaction analysis among oncogenesis-related genes revealed novel genes and networks in lung cancer development.
Oncotarget. 2019 Mar 05;10(19):1760-1774
The Impact of Brain Metastases and Associated Neurocognitive Aspects on Health Utility Scores in EGFR Mutated and ALK Rearranged NSCLC: A Real World Evidence Analysis.
Oncologist. 2019 Apr 05;:
Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study.
Lancet Respir Med. 2019 Apr;7(4):347-357
Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer.
Curr Oncol. 2019 Feb;26(1):e81-e93
Clin Lung Cancer. 2018 Dec 22;:
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Associate Professor, Department of Medicine, University of Toronto
President, Lung Cancer Canada
Chair, Working Group on Economic Analysis, National Cancer Institute of Canada Clinical Trials Group